Atara Biotherapeutics (ATRA) Revenue & Revenue Breakdown
Atara Biotherapeutics Revenue Highlights
Latest Revenue (Y)
$128.94M
Atara Biotherapeutics Revenue by Period
Atara Biotherapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $128.94M | 1404.02% |
| 2023-12-31 | $8.57M | -86.51% |
| 2022-12-31 | $63.57M | 212.55% |
| 2021-12-31 | $20.34M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Atara Biotherapeutics generated $128.94M in revenue during NA 2024, up 1404.02% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Atara Biotherapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | - | -100.00% |
| 2025-06-30 | $17.57M | -82.09% |
| 2025-03-31 | $98.15M | 199.66% |
| 2024-12-31 | $32.75M | -18.50% |
| 2024-09-30 | $40.19M | 40.33% |
| 2024-06-30 | $28.64M | 4.69% |
| 2024-03-31 | $27.36M | 543.39% |
| 2023-12-31 | $4.25M | 98.88% |
| 2023-09-30 | $2.14M | 123.41% |
| 2023-06-30 | $957.00K | -21.94% |
| 2023-03-31 | $1.23M | 454.75% |
| 2022-12-31 | $221.00K | -95.04% |
| 2022-09-30 | $4.46M | -91.36% |
| 2022-06-30 | $51.58M | 605.21% |
| 2022-03-31 | $7.31M | -3.10% |
| 2021-12-31 | $7.55M | 40.56% |
| 2021-09-30 | $5.37M | 38.76% |
| 2021-06-30 | $3.87M | 8.95% |
| 2021-03-31 | $3.55M | -99.01% |
| 2020-12-31 | $358.19M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | - |
Atara Biotherapeutics generated - in revenue during Q3 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Atara Biotherapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| COYA | Coya Therapeutics | $3.55B | $3.56B |
| MGNX | MacroGenics | $149.96M | $22.24M |
| ATRA | Atara Biotherapeutics | $128.94M | - |
| STRO | Sutro Biopharma | $62.04M | $9.69M |
| STTK | Shattuck Labs | $5.72M | - |
| ORMP | Oramed Pharmaceuticals | $1.34M | - |
| OVID | Ovid Therapeutics | $566.00K | $132.00K |
| CLNN | Clene | $342.00K | $15.00K |
| IFRX | InflaRx | $61.80K | $36.25K |
| CNTX | Context Therapeutics | - | - |
| CSBR | Champions Oncology | - | - |